bioAffinity Technologies, Inc.

Analysis for Ticker: BIAF

BioAffinity Technologies is a company that claims to fight lung cancer by using artificial intelligence to analyze spit samples. The reality is that the business is a machine designed to burn cash for the benefit of a small group of insiders and financiers. By 12/2025 the company had built an accumulated deficit of 68,6$ million. The math is a disaster because the company spends millions of dollars on family salaries and buying research labs while making almost no money from its actual products. To stay alive they use a trick called dilution. Think of the company like a pizza. To pay their bills the bosses keep cutting the pizza into more and more tiny slices to sell to new people. If you already own a slice it gets smaller every time they print a new share because your part of the whole pizza is shrinking.